API reference
Agomelatine
- CAS number
- 138112-76-2
- Molecular formula
- C15H17NO2
- Molecular weight
- 243.3 g/mol
About this molecule
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. The Committee for Medical Products for Human Use (CHMP) recommended refusal of marketing authorization on 27 July 2006. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
- InChIKey
- YJYPHIXNFHFHND-UHFFFAOYSA-N
- SMILES
- CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC
- PubChem CID
- 82148
Also known as
Agomelatine · Thymanax · Valdoxan · Agomelatina · AGO-178 · N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide · agomelatinum · AGO178
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.